Tirzepatide Research: Dual GIP/GLP-1 Receptor Signaling

Tirzepatide is a synthetic peptide that activates two incretin receptors at once — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is one of the most heavily studied metabolic peptides in modern clinical research. Because extensive human trial data exist, this summary describes what those trials reported; it is not a description of any use of our product, which is supplied for laboratory Research Use Only.

A dual incretin agonist

The incretin system links the gut to insulin signaling. Tirzepatide was designed to engage both the GIP and GLP-1 receptors simultaneously — a “dual agonist” — and reviews summarize how this combined mechanism is studied for glucose and energy metabolism (Nauck & D'Alessio, Cardiovasc Diabetol, 2022). [1] Pharmacology work further characterizes it as a biased, imbalanced agonist at the two receptors, which is an active area of mechanistic research.

The clinical-research record

Tirzepatide's human research is unusually extensive. The SURPASS program studied it in type-2-diabetes populations versus comparators (Rosenstock et al., Lancet, 2021), [2] and the SURMOUNT-1 trial studied it for body-weight outcomes in obesity research (Jastreboff et al., N Engl J Med, 2022). [3] These are large randomized trials — the reason tirzepatide dominates metabolic-research conversations.